Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review

Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: احسان احمدپور

کلمات کلیدی: SAG1 Toxoplasma gondii DNA vaccine Protein vaccine Immunization

نشریه: 7771 , 7 , 69 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله احسان احمدپور
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های عفونی و گرمسیری
کد مقاله 70939
عنوان فارسی مقاله Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review
عنوان لاتین مقاله Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review
ناشر 10
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Systematic Review Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Toxoplasma gondii is an intracellular parasite that infects a broad range of animal species and humans. As the main surface antigen of the tachyzoite, SAG1 is involved in the process of recognition, adhesion and invasion of host cells. The aim of the current systematic review study is to clarify the latest status of studies in the literature regarding SAG1-associated recombinant proteins or SAG1-associated recombinant DNAs as potential vaccines against toxoplasmosis. Data were systematically collected from six databases including PubMed, Science Direct, Web of Science, Google Scholar, EBSCO and Scopus, up to 1st of January 2019. A total of 87 articles were eligible for inclusion criteria in the current systematic review. The most common antigens used for experimental cocktail vaccines together with SAG1 were ROP2 and SAG2. In addition, the most parasite strains used were RH and ME49. Freund’s adjuvant and cholera toxin have been predominantly utilized. Furthermore, regarding the animal models, route and dose of vaccination, challenge methods, measurement of immune responses and cyst burden have been discussed in the text. Most of these experimental vaccines induce immune responses and have a high degree of protection against parasite infections, increase survival rates and duration and reduce cyst burdens. The data demonstrated that SAG1 antigen has a high potential for use as a vaccine and provided a promising approach for protecting humans and animals against toxoplasmosis. 1. Introduction Toxoplasma gondii is an obligate intracellular parasite belonging to the phylum Apicomplexa with an exceptionally broad host range such as most species of domestic animals, birds and humans in most parts of the world [1]. It is estimated that up to 1 billion people worldwide are infected with this parasite. T. gondii is the etiologic agent of toxoplasmosis and is usually asymptomatic in immunocompetent individuals. However, T. gondii may cause serious diseases or death in individuals with compromised immune response such as acquired immunodeficiency syndrome (AIDS), cancer, and organ transplant recipients, or during pregnancy, if not treated, it can cause serious adverse effects for the fetus and the newborn. It can lead to maternal-fetal vertical transmission and result in chorioretinitis, miscarriage, stillbirth, congenital

نویسندگان
hide/show

نویسنده نفر چندم مقاله
احسان احمدپورپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
75- Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate.pdf1398/11/081045288دانلود